Document is current
Any future updates will be listed below
-
Authors
Dey, Ranadhir https://orcid.org/0000-0003-0069-7867
Alshaweesh, Jalal
Singh, Kamaleshwar P.
Lypaczewski, Patrick https://orcid.org/0000-0002-5550-712X
Karmakar, Subir
Klenow, Laura
Paulini, Kayla https://orcid.org/0000-0001-9379-9509
Kaviraj, Swarnendu
Kamhawi, Shaden https://orcid.org/0000-0003-4304-636X
Valenzuela, Jesus G. https://orcid.org/0000-0002-5589-9450
Singh, Sanjay
Hamano, Shinjiro https://orcid.org/0000-0003-3881-8337
Satoskar, Abhay R. https://orcid.org/0000-0001-5989-1520
Gannavaram, Sreenivas https://orcid.org/0000-0002-6557-8220
Nakhasi, Hira L. https://orcid.org/0000-0003-4941-1620
Matlashewski, Greg https://orcid.org/0000-0002-8971-5525
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 26 January 2023
Accepted: 19 October 2023
First Online: 2 November 2023
Competing interests
: The authors declare the following competing interests: The FDA is currently a co-owner of two US patents that claim attenuated Leishmania species with the Centrin gene deletion (US7,887,812 and US 8,877,213). K.P.S., Subir Karmakar, Swarnendu Kaviraj and S.S. are employees of Gennova Biopharmaceuticals. The remaining authors declare no competing interests.
